A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

NCT ID: NCT03545971

Last Updated: 2023-02-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-25
• Study Completion Date: 2022-08-09

Brief Summary

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients with advanced solid tumors(Ia) and advanced melanoma(Ib).

Detailed Description

Phase Ia study will adopt the classical 3+3 dose escalation design. The starting dose is 0.3 mg/kg, followed by 3 dose cohorts (1mg/kg, 2mg/kg and 3mg/kg). Duration of dose limiting toxicity (DLT) observation period is 21 days. IBI310 treatment q3w, up to 3 cycles, will be provided to patients who complete DLT observation period.

Efficacy will primarily be evaluated by RECIST v1.1. Patient safety will be monitored throughout the study. Pharmacokinetic/pharmacodynamics and immunogenicity will be assessed throughout the study.

Phase Ib study will evaluate the tolerability and safety of IBI310 combined with Sintilimab in patients with advanced melanoma. Phase Ib of the study will begin after DLT observation is completed in certain dose cohorts.

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ia Cohort A

Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Ia Cohort B

Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Ia Cohort C

Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Ia Cohort D

High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Ib Cohort A

3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Sintilimab

Intervention Type: DRUG

PD-1 monoclonal antibody

Ib Cohort A2

low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Sintilimab

Intervention Type: DRUG

PD-1 monoclonal antibody

Ib Cohort B

3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Sintilimab

Intervention Type: DRUG

PD-1 monoclonal antibody

Ib Cohort B2

low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.

Group Type: EXPERIMENTAL

IBI310

Intervention Type: DRUG

IBI310 is anti CTLA-4 antibody

Sintilimab

Intervention Type: DRUG

PD-1 monoclonal antibody

Interventions

IBI310

IBI310 is anti CTLA-4 antibody

Intervention Type: DRUG

Sintilimab

PD-1 monoclonal antibody

Intervention Type: DRUG

Other Intervention Names

CTLA-4

Eligibility Criteria

Inclusion Criteria

1. Patients with locally advanced, recurrent or metastatic solid tumors who failed standard treatment(applicable to the Ia period).

2. Patients with advanced, recurrent or metastatic melanoma confirmed by cytology or histology (applicable to the Ib period).

3. Signed written informed consent form and willing and able to comply with scheduled visits and other requirements of the study.

4. ≥18，and ≤70 years.

5. Life expectancy of at least 12 weeks.

6. At least 1 measurable lesion per RECIST v1.1(long axis>15mm or short axis>10mm)

7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1.

8. Patients of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study medication.

9. Adequate organ and bone marrow function.

Exclusion Criteria

1. Prior exposure to any anti-CTLA-4, anti-PD-1 or anti-PD-L1/L2 antibody.

2. Received any investigational agent within 4 weeks of the first dose of study medication.

3. Received last dose of anti-tumor therapy (chemotherapy, endocrine therapy, targeted therapy, tumor immunotherapy or arterial embolization) within 4 weeks of the first dose of study medication.

4. Received treatment with corticosteroids (>10mg daily prednisone equivalent) or other immunosuppressive medications within 4 weeks before the first dose of study medication. Nasal spray, inhalation, or other ways of topical corticosteroids or physiological doses of systemic corticosteroids are not included.

5. Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.

6. Active, known or suspected autoimmune disease or has a history of the disease within the last 2 years (Patients with vitiligo, psoriasis, alopecia or Grave's disease, hypothyroidism requiring hormone replacement, or type I diabetes mellitus only requiring insulin replacement, but not required systemic treatment in the last 2 years, are permitted to enroll)

7. Known primary immunodeficiency

8. Active tuberculosis

9. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation

10. Known allergy or hypersensitivity to any other monoclonal antibodies or IBI310 and/or any components used in their preparation.

11. Known acute or chronic active hepatitis B (HBV DNA positive and HBV DNA copies ≥1×103/ml or ≥200IU/ml) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection. Patients with HCV antibody positive but HCV RNA negative are permitted to enroll.

12. Patients with a history of interstitial lung disease

13. Uncontrolled third space effusion, eg. ascites or pleural effusion cannot be drained or controlled.

14. Women who are pregnant or nursing.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

CIBI310A101

Identifier Type: -

Identifier Source: org_study_id